Guangzhou Wondfo Biotech (300482) Fundamentals 2026 — Revenue Analysis | SniperIQ
Guangzhou Wondfo Biotech (300482) is a CN-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of ¥7.8B, trading at ¥16.68 on the SHZ. This SniperIQ fundamentals page covers Guangzhou Wondfo Biotech's valuation, profitability (net margin -9.0%), revenue (¥2.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Guangzhou Wondfo Biotech's market cap?
Guangzhou Wondfo Biotech (300482) has a market capitalization of approximately ¥7.8B, trading at ¥16.68 on the SHZ. Market cap moves with the live share price.
What is Guangzhou Wondfo Biotech's P/E ratio?
Guangzhou Wondfo Biotech's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Guangzhou Wondfo Biotech?
Guangzhou Wondfo Biotech runs a net profit margin of -9.0%, a gross margin of 55.0%, and an operating margin of -12.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Guangzhou Wondfo Biotech generate?
Guangzhou Wondfo Biotech reported revenue of ¥2.1B for fiscal year 2025, with net income of -¥63M and earnings per share (EPS) of -0.13. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Guangzhou Wondfo Biotech pay a dividend?
Guangzhou Wondfo Biotech offers a trailing dividend yield of about 1.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Guangzhou Wondfo Biotech financially healthy?
Guangzhou Wondfo Biotech carries a debt-to-equity ratio of 0.12x and a current ratio of 3.22x, with a market beta of 0.87. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Guangzhou Wondfo Biotech a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Guangzhou Wondfo Biotech (300482) the key facts are: market cap ¥7.8B, revenue ¥2.1B, 52-week range 16-26.29. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Guangzhou Wondfo Biotech's full fundamentals live
Get Guangzhou Wondfo Biotech's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.